AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 15, 2024 07:29 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
Movember Canada’s 2024 Partnerships Roster Has Something for Everyone
November 13, 2024 09:04 ET
|
Movember Canada
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calling all golfers, shoppers, foodies, gym goers, hockey fans and more! Movember is excited to share the many different partnerships activating throughout...
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
November 12, 2024 16:05 ET
|
Turnstone Biologics Corp.
Turnstone reports third quarter 2024 financial results and provides recent business highlights
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
TransCode Therapeutics Open Letter to Shareholders
November 12, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Open Letter to Shareholders
Peptide Therapeutics Market Size to Surpass USD 76.11 Billion by 2033 | Straits Research
November 11, 2024 10:10 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Researchers have used peptides to deliver drugs to target cells due to their remarkable efficacy and selectivity towards the different...
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 11, 2024 07:00 ET
|
EvolveImmune
Poster Presentations Spotlight Differentiated Therapeutic Profile and Precision Therapeutic Strategy for Lead Development Candidate EVOLVE104 as Program Advances Toward Clinic for Solid Tumors EVOLVE...